Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328012760> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4328012760 endingPage "2032" @default.
- W4328012760 startingPage "2032" @default.
- W4328012760 abstract "ObjectivesEvaluation of treatment of type-I retinopathy of prematurity (ROP) detected by early screening of preterm infants by intravitreal injection of Ranibizumab.BackgroundRetinopathy of prematurity is a childhood-blindness disease. Considering Ranibizumab might have a better safety profile for preterm infants, some authors shifted IVB to intravitreal injection of Ranibizumab to treat ROP.Patients and methodsA clinical trial was performed between January 2021 and May 2022 in the neonatal ICU and Department of Ophthalmology, Menoufia University on 131 preterm infants. Type-I ROP cases were diagnosed and treated with intravitreal injection (IVI) of antivascular endothelial growth factor Ranibizumab 0.25 mg/0.025 ml. Injection was done 1.5 mm posterior to limbus. Both eyes were injected in the same sitting with different sterile sets. Follow-up was performed after 1 day to IVI, 1 week, and then according to stage of ROP.ResultsThirty patients developed ROP severe enough to require intervention. Five (38.50%) cases had stage 2, five (38.50%) cases had stage 3, and three (23.10%) cases had aggressive posterior retinopathy of prematurity. The mean gestational age for type-1 ROP cases was 30 ± 1.8 weeks (28–35 weeks), mean birth weight was 1.3 ± 0.3 (0.950–1.6), and mean postmenstrual age was 34 ± 2. The mean follow-up time was 14 ± 1.37 months (range, 12–24 months). The efficacy of IVI of Ranibizumab in our study is 21 (80.7%) of 26 and recurrence requiring treatment occurred in five eyes from 26 (19.2%) eyes.ConclusionSingle dose of Ranibizumab improving type-I ROP as regression of plus disease and newly formed vessels, and allows for continued vessel growth into the peripheral retina." @default.
- W4328012760 created "2023-03-22" @default.
- W4328012760 creator A5032666523 @default.
- W4328012760 creator A5034964494 @default.
- W4328012760 creator A5082534560 @default.
- W4328012760 date "2022-01-01" @default.
- W4328012760 modified "2023-10-01" @default.
- W4328012760 title "Evaluation of treatment of retinopathy of prematurity by intravitreal injection of Ranibizumab: a clinical trial" @default.
- W4328012760 cites W2021381232 @default.
- W4328012760 cites W2744248085 @default.
- W4328012760 cites W2810455825 @default.
- W4328012760 cites W2893226105 @default.
- W4328012760 cites W2905311732 @default.
- W4328012760 doi "https://doi.org/10.4103/mmj.mmj_285_22" @default.
- W4328012760 hasPublicationYear "2022" @default.
- W4328012760 type Work @default.
- W4328012760 citedByCount "0" @default.
- W4328012760 crossrefType "journal-article" @default.
- W4328012760 hasAuthorship W4328012760A5032666523 @default.
- W4328012760 hasAuthorship W4328012760A5034964494 @default.
- W4328012760 hasAuthorship W4328012760A5082534560 @default.
- W4328012760 hasConcept C118487528 @default.
- W4328012760 hasConcept C141071460 @default.
- W4328012760 hasConcept C187212893 @default.
- W4328012760 hasConcept C2776694085 @default.
- W4328012760 hasConcept C2777091541 @default.
- W4328012760 hasConcept C2777802072 @default.
- W4328012760 hasConcept C2778376644 @default.
- W4328012760 hasConcept C2779234561 @default.
- W4328012760 hasConcept C2779918416 @default.
- W4328012760 hasConcept C2781100027 @default.
- W4328012760 hasConcept C54355233 @default.
- W4328012760 hasConcept C66322754 @default.
- W4328012760 hasConcept C71924100 @default.
- W4328012760 hasConcept C86803240 @default.
- W4328012760 hasConceptScore W4328012760C118487528 @default.
- W4328012760 hasConceptScore W4328012760C141071460 @default.
- W4328012760 hasConceptScore W4328012760C187212893 @default.
- W4328012760 hasConceptScore W4328012760C2776694085 @default.
- W4328012760 hasConceptScore W4328012760C2777091541 @default.
- W4328012760 hasConceptScore W4328012760C2777802072 @default.
- W4328012760 hasConceptScore W4328012760C2778376644 @default.
- W4328012760 hasConceptScore W4328012760C2779234561 @default.
- W4328012760 hasConceptScore W4328012760C2779918416 @default.
- W4328012760 hasConceptScore W4328012760C2781100027 @default.
- W4328012760 hasConceptScore W4328012760C54355233 @default.
- W4328012760 hasConceptScore W4328012760C66322754 @default.
- W4328012760 hasConceptScore W4328012760C71924100 @default.
- W4328012760 hasConceptScore W4328012760C86803240 @default.
- W4328012760 hasIssue "4" @default.
- W4328012760 hasLocation W43280127601 @default.
- W4328012760 hasOpenAccess W4328012760 @default.
- W4328012760 hasPrimaryLocation W43280127601 @default.
- W4328012760 hasRelatedWork W1980935798 @default.
- W4328012760 hasRelatedWork W1991151698 @default.
- W4328012760 hasRelatedWork W2004228627 @default.
- W4328012760 hasRelatedWork W2048288464 @default.
- W4328012760 hasRelatedWork W2070322992 @default.
- W4328012760 hasRelatedWork W2127045213 @default.
- W4328012760 hasRelatedWork W2335265048 @default.
- W4328012760 hasRelatedWork W2780688356 @default.
- W4328012760 hasRelatedWork W2792964360 @default.
- W4328012760 hasRelatedWork W4284701438 @default.
- W4328012760 hasVolume "35" @default.
- W4328012760 isParatext "false" @default.
- W4328012760 isRetracted "false" @default.
- W4328012760 workType "article" @default.